Intratracheal transplantation of alveolar type II cells reverses bleomycin-induced lung fibrosis by Serrano-Mollar, Anna et al.
Intratracheal Transplantation of Alveolar Type II Cells
Reverses Bleomycin-induced Lung Fibrosis
Anna Serrano-Mollar1,2, Maria Nacher1, Gemma Gay-Jordi1, Daniel Closa1, Antoni Xaubet2,3, and Oriol Bulbena1
1Department of Experimental Pathology, Institut d’Investigacions Biome`diques de Barcelona, Consejo Superior de Investigaciones Cientı´ficas,
Institut d’Investigacions Biome`diques August Pi i Sunyer, Barcelona, Spain; 2Centro de Investigacio´n Biome´dica en Red (CIBER)
de Enfermedades Respiratorias, Barcelona, Spain; and 3Servei de Pneumologia, Institut Clı´nic del To´rax, Hospital Clı´nic, Barcelona, Spain
Rationale: Transplantation of stem cells has been proposed as a
strategy for repair of lung fibrosis. Nevertheless, many studies have
yielded controversial results that currently limit the potential use of
these cells as an efficient treatment. Alveolar type II cells are the
progenitor cells of the pulmonary epitheliumand usually proliferate
after epithelial cell injury. During lung fibrosis, however, the altered
regeneration process leads to uncontrolled fibroblast proliferation.
Objectives: To investigate whether intratracheal transplantation of
isolated alveolar type II cells can halt and reverse the fibrotic process
in an experimentalmodel of bleomycin-induced lungfibrosis in rats.
Methods: Lungfibrosiswas induced in syngeneic female Lewis rats by
a single intratracheal instillation of bleomycin (2.5 U/kg). Animals
were transplanted with alveolar type II cells from male animals at
a dose of 2.5 3 106 cells per animal 3, 7, and 15 days after endo-
tracheal bleomycin instillation. Animals were killed 21 days after the
induction of lung fibrosis.
Measurements and Main Results: Lung fibrosis was assessed by his-
tologic studyanddeterminationofhydroxyproline content. Engraft-
ment of transplanted cells was measured by real-time polymerase
chain reaction for the Y chromosome and by fluorescence in situ
hybridization for the Y chromosome. Transplantation of alveolar
type II cells into damaged lung 3, 7, or 15 days after bleomycin
instillation led to reduced collagen deposition, and reduction in the
severity of pulmonary fibrosis.
Conclusions: This study demonstrates the potential role of alveolar
type II cell transplantation in designing future therapies for lung
fibrosis.
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Idiopathic pulmonary fibrosis is a chronic inflammatory intersti-
tial lung disease that has a potentially fatal prognosis, with death
occurring in most patients within 5 years of diagnosis. Conven-
tional therapy consists of glucocorticoids or immunosuppressive
drugs, which are usually ineffective in preventing the progres-
sion of fibrosis (1). A number of studies showed that stem cells
derived from adult tissues could differentiate into lung epithelial
cells and confer a functional benefit (2–7). Therefore, the con-
tribution of adult stem cells to the regeneration of lung tissue
was considered an alternative approach to the treatment of certain
lung diseases. However, despite these promising results, studies
have failed to restore lung epithelium with adult stem cells (8–10).
Classically, the progenitor cells of the pulmonary epithelium
are considered to be the alveolar type II cells in the alveoli.
Alveolar type II cells are reparative in nature, rapidly pro-
liferating and differentiating into alveolar type I cells after
epithelial cell injury. However, idiopathic lung fibrosis is
characterized by the fact that both alveolar type II and type I
cells die, and are replaced by abundant fibroblasts (11). On the
basis of this evidence, loss of alveolar type II cells compromises
the reparative mechanism and is thought to play a signifi-
cant role in the development and progression of pulmonary
fibrosis.
Bleomycin (BLM) instillation in rat lungs causes an inflam-
matory process that results in pulmonary fibrosis with lesions
distributed heterogeneously, resembling the natural progression
of the human disease, for example, patchy parenchymal inflam-
mation of variable intensity, epithelial cell injury with reactive
hyperplasia, basement membrane damage, and interstitial as
well as intraalveolar fibrosis. Hence this model has been widely
used to study the regulation of lung fibrosis (12).
In the current investigation, we have performed intra-
tracheal transplantation of isolated alveolar type II cell in
a rat model of BLM-induced lung fibrosis to evaluate the abil-
ity of these cells to repair damaged lung tissue. We observed
the reparative effect of alveolar type II cells transplanted at
three different times after fibrosis induction, corresponding to
the three different phases of the development of BLM-induced
lung fibrosis. The first phase, 3 days after BLM instillation, is
characterized by apoptosis and necrosis of alveolar epithelial
cells, followed by prominent infiltration of lymphocytes (13).
The second phase, 7 days after BLM instillation, is associated
with the release of various cytokines that promote the de-
velopment of lung fibrosis (14–16). The third phase, 15 days
after BLM instillation, represents the full development of the
disease and is characterized by enhanced collagen deposition
inside the lung and by expansion of the lung interstitium
resulting from the proliferation of fibroblasts and smooth
muscle cells (14–16).
We report here that the transplantation of alveolar type II
cells is effective in preventing lung fibrosis.
AT A GLANCE COMMENTARY
Scientific Knowledge on the Subject
Idiopathic pulmonary fibrosis is a fibroproliferative disor-
der characterized histopathologically by heterogeneous
interstitial fibrosis with fibroblastic foci and honeycomb
lung. At present no treatment has proven beneficial to
survival.
What This Study Adds to the Field
Transplantation of alveolar type II cells is successful in
reversing lung fibrosis in the experimental bleomycin
model in rats.
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METHODS
Animals
Syngeneic Lewis rats, weighing 170–200 g at the beginning of the
experiment, were used according to European Community (Directive
86/609/EEC) and Spanish guidelines for the treatment of experimental
animals.
BLM-induced Lung Fibrosis
Pulmonary fibrosis was induced in female animals by intratracheal
instillation of a sublethal dose of BLM (2.5 U/kg) dissolved in 400 ml of
sterile saline under halothane anesthesia (17). Control animals received
the same volume of saline. During the experiment, animal body
weights were recorded every 2 days.
Purification of Alveolar Type II Cells
Fresh alveolar type II cells were isolated from healthy male donor
animals. The protocol for purification has been described elsewhere
(18). Briefly, to isolate alveolar type II cells, the lungs were removed
from each animal and lavaged six times, each time with 8 ml of saline.
The lungs were digested with 0.25% trypsin (T8003; Sigma, St. Louis,
MO) dissolved in saline (100 ml) and suspended in 0.9% NaCl at 378C
for 30 minutes. The trypsin was constantly topped up during the 30-
minute expansion of the parenchyma.
After digestion, the lungs were chopped into 1- to 2-mm2 cubes,
treated with DNase dissolved in saline (7,500 U/100 ml), and filtered
through nylon meshes ranging in pore size from 150 to 30 mm. The
resulting cell suspension was centrifuged (250 3 g, 20 min at 108C)
through a sterile Percoll gradient and the alveolar type II cell–rich
band was removed. A second DNase treatment (2,000 U/100 ml) was
administered and the cells were recovered as a pellet by centrifugation
at 250 3 g for 20 minutes. These cells were resuspended in 5 ml of
DCCM-1 (Biological Industries, Kibbutz Beit Haemek, Israel) supple-
mented with a 2% (wt/vol) L-glutamine and subjected to differential
attachment on a plastic Petri dish. No adherent alveolar type II cells
were collected after 2 hours and cells were counted to establish the
final yield of freshly purified cells.
Alveolar type II cell viability was assessed with trypan blue
(Sigma), showing greater than 95% viability. Cell yield and purity
was assessed with an alkaline phosphatase staining kit (Sigma). Cells
were cytocentrifuged (Cytospin 3; Shandon Scientific Ltd, Grupo
Taper, Madrid, Spain) and cell smears were allowed to air dry and
were stained for 15 minutes at room temperature. Staining was con-
ducted according to the manufacturer’s protocol for the use of alkaline
phosphatase (18). Cells were evaluated by transmission electron mi-
croscopy. The cells were fixed in 2.5% glutaraldehyde in phosphate
buffer (0.1 mol/L, pH 7.4) for at least 2 hours at 48C. The cells were
secondarily fixed in 1% osmium tetroxide and 0.8% potassium ferro-
cyanide for 1 hour at 48C. After three washes with cold double-distilled
water, the samples were dehydrated through an ascending concentra-
tion of acetone (30, 50, 70, 95, and 100%), and three changes of 100%
acetone. They were then embedded in Spurr resin and polymerized at
608C. The embedded blocks were sectioned with a diamond knife
(Diatome, Biel, Switzerland) on a Leica Ultracut UCT (Leica Micro-
systems, Deerfield, IL). Ultrathin sections were placed on copper grids
and stained with uranyl acetate and lead citrate before examination
with a JEM 1010 (JEOL Ltd., Tokyo, Japan) equipped with a Gatan/
BioScan digital camera (Gatan, Inc., Pleasanton, CA).
Cell yield, purity, and characterization of freshly isolated alveolar
type II cells were established by the presence of intracellular alkaline
phosphatase (Figure 1A), and of lamellar bodies and microvilli
(Figures 1B and 1C) at the electron microscope level. More than
86% (n 5 4) of purified rat cells stained positively for alkaline
phosphatase.
Experimental Groups
Animals were randomly distributed into six experimental groups (n5 8
for each group):
Control: Saline instillation
Control plus transplantation: Saline instillation followed by alveolar
type II cell transplantation 3 days after instillation
BLM: Bleomycin instillation
BLM plus transplantation (3 d): Bleomycin instillation plus alveolar
type II transplantation 3 days after instillation
BLMplus transplantation (7 d): Bleomycin instillation plus alveolar type II
transplantation 7 days after instillation
BLM plus transplantation (15 d): Bleomycin instillation plus alveolar
type II transplantation 15 days after instillation
Transplantation Procedure
On Days 3, 7, and 15 after endotracheal BLM administration, female
recipient animals were transplanted with alveolar type II cells endo-
tracheally, by the transoral route under halothane anesthesia. Each
animal received a dose of 2.5 3 106 cells suspended in 400 ml of sterile
saline. The control group received the same dose of cells 3 days after
saline instillation. Animals were killed 21 days after induction of lung
fibrosis.
Real-time Polymerase Chain Reaction
The engraftment of donor alveolar type II cells was evaluated by ex-
amination of the lung genomic DNA of the transplanted animals, using
the real-time polymerase chain reaction (PCR) as described (19) and
an iCycler iQ5 real-time PCR detection system (Bio-Rad Laboratories,
Hercules, CA) using PCR Y chromosome primers 59-CTG-GCT-CTG-
CTC-CTA-CCT-ATG-C-39 and 59ATT-CTC-CTT-TCT-TAC-ACA-
CTA-CAC-ATC-C-39 and an iQ SYBR Green supermix kit (Bio-Rad
Laboratories). Standard curves were generated by serially diluting
male rat genomic DNA into female rat genomic DNA prepared from
liver.
Fluorescence In Situ Hybridization for the Y Chromosome
Fluorescence in situ hybridization (FISH) assays of formalin-fixed
tissue sections were performed to identify the Y chromosomes. Briefly,
paraffin sections of 4 mm were deparaffinized and incubated in saline–
sodium citrate (43 SSC buffer, pH 7.0) for 30 minutes, and then the
slides were incubated in 1 M sodium isothiocyanate at room temper-
ature overnight. Slices were incubated in pepsin for 5 minutes and
washed twice in phosphate-buffered saline (PBS) for 5 minutes, washed
once with formaldehyde-PBS–MgCl2 for 1.5 minutes and with PBS for
1.5 minutes, then followed by serial ethanol dehydration steps (1.5 min
each). Sections were denatured at 658C for 2 minutes in preheated 70%
formamide and 23 SSC buffer, pH 7.0, and subsequently ‘‘quenched’’
with ice-cold 70% ethanol for 1.5 minutes. Serial ethanol dehydration
was done again. The rat Y chromosome probe labeled with fluorescein
isothiocyanate (Star*FISH; Cambio, Cambridge, UK) was denatured
at 658C for 10 minutes and applied to the sections at 458C. The sections
were coverslipped and sealed with rubber cement for incubation
overnight in a hydrated slide box at 428C. Coverslips were carefully
removed in preheated 23 SSC buffer, pH 7.0, at 458C. Sections were
preheated in 50% formamide in 23 SSC buffer for 5 minutes each at
458C and gently washed twice in preheated 0.13 SSC buffer for 5
minutes each at 458C. Sections were observed by confocal microscopy.
Confocal images were acquired with a Leica TCS SL laser-scanning
confocal spectral microscope (Leica Microsystems Heidelberg GmbH,
Mannheim, Germany) with argon and helium–neon lasers attached to
a Leica DMIRE2 inverted microscope. Fluorescein isothiocyanate and
propidium iodide emission were acquired sequentially with a triple
dichroic beam splitter (TD 488/543/633 nm) and emission detection
ranges of 500–535 and 592–700 nm, respectively. All images were
obtained with a 363 oil immersion objective lens (numeric aperture,
1.32) equipped with phase-contrast optics and a confocal pinhole set-
ting of 1 Airy unit. Because of the small size of the cells an electronic
zoom (32) was necessary for stronger magnification and better image
resolution. Image assembly and treatment were performed with image-
processing Leica confocal software.
Hydroxyproline Content
Lung hydroxyproline content was measured as an indicator of collagen
deposition by the method outlined by Woessner (20). Samples were
homogenized and then hydrolyzed in 6 M HCl for 18 hours at 1108C.
The hydrolysate was then neutralized with 2.5 M NaOH. Aliquots
1262 AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE VOL 176 2007
(2 ml) were analyzed for hydroxyproline content after addition of 1 ml
of chloramine-T, 1 ml of perchloric acid, and 1 ml of dimethylamino-
benzaldehyde. Samples were read for absorbance at 550 nm in a spec-
trophotometer. Results are expressed as micrograms of hydroxyproline
per lung.
Histology
For histologic studies, the left lung was perfused via its main bronchus
with a fixative solution (10% neutral-buffered formalin) at a pressure
of 25 cm H2O and immersed in the fixative for 12 6 24 hours. Lung
tissue blocks were then taken and placed in formalin, dehydrated in
a graded series of ethanol, embedded in paraffin, cut into 4-mm-thick
serial sections, and stained with hematoxylin–eosin and Masson’s tri-
chrome to identify inflammatory cells, connective tissue, and collagen
deposition.
Macrophage Transplantation
An additional experiment involving macrophage transplantation was
performed as a control, using an unrelated cell type to determine
whether the fibrotic reversal response was specific for alveolar type II
cells. Fresh macrophages were isolated from healthy male donor
animals by performing bronchoalveolar lavage. Bronchoalveolar la-
vage fluid was obtained by washing the lungs four times with 10-ml
saline aliquots through a tracheal cannula and centrifuged (300 3 g, 20
min, 48C). Cell viability was assessed with trypan blue and was greater
than 95%. To evaluate the cell yield and purity and to characterize
freshly isolated macrophages, Cytospin preparations were stained with
Diff-Quik (Diagnostics Grifols SA, Barcelona, Spain) according to the
manufacturer’s protocol. More than 95% (n 5 4) of rat bronchoalveo-
lar cells were macrophages (see Figure 5A).
On Day 15 after bleomycin instillation, female recipient animals
were transplanted with macrophages endotracheally, by the transoral
route under halothane anesthesia, at a dose of 2.5 3 106 cells per
animal. The cells were suspended in 400 ml of sterile saline. The control
group received the same dose of cells 15 days after saline instillation.
Animals were killed 21 days after the induction of lung fibrosis. The
animals were randomly distributed into four experimental groups (n 5
8 for each group):
Control: Saline instillation
Control plus transplanted macrophages: Saline instillation plus macro-
phage transplantation 15 days after instillation
BLM: Bleomycin instillation
BLM plus transplanted macrophages (15 d): Bleomycin instillation plus
macrophage transplantation 15 days after instillation
Statistical Analysis
Data are expressed as means (SEM) with 95% confidence intervals.
Statistical analysis was performed by analysis of variance followed by
appropriate post hoc tests including the Newman-Keuls test when
differences were significant (GraphPad Software, Inc., San Diego, CA).
A P value less than 0.05 was considered significant.
RESULTS
BLM instillation initially causes a marked loss in body weight,
which is normally recovered later. After alveolar type II cell
transplantation, animals regained weight more quickly than did
BLM nontransplanted animals (Figure 2A). This indicated that
alveolar type II cell transplantation enhanced the health of the
animals.
After lung collection, the macroscopic appearance of BLM
nontransplanted lungs was fibrotic. They were large, yellowish
and had several scars when compared with saline control lungs
(Figure 2B). In contrast, BLM transplanted lungs showed
an improved appearance similar to that of the saline control
lungs and were devoid of scars (Figure 2B). Figure 2C shows
Masson’s trichrome–stained lung sections examined by stereo-
microscopy to illustrate the heterogeneous topography of the
fibrotic lesions (patchy areas of lung fibrosis); BLM nontrans-
planted lungs showed extensive areas of fibrosis compared with
BLM transplanted lungs.
BLM instillation caused an increase in lung weight owing to
the inflammatory and fibrotic component (17). Lung weight was
significantly decreased in the transplanted groups 7 and 15 days
after BLM instillation compared with the BLM nontransplanted
group (Figure 2D).
Because alveolar type II cell transplant donors and recipients
were sex-mismatched, engraftment levels of male donor–de-
rived cells in the lungs of female transplant recipients were
quantified by real-time PCR (19). No male DNA was detected
in the control transplant animals. We found 0.18, 0.30, and
0.49% male DNA in the transplanted groups 3, 7, and 15 days
after BLM, respectively (Figure 3A). These data demonstrate
that the engraftment of alveolar type II cells is more effective
when fibrosis has developed than in its early phases.
In addition, the successful engraftment of male donor cells in
the female transplanted animals was assessed by FISH of the Y
chromosome. FISH analysis was performed in paraffin-embedded
sections of lung tissue, using Y chromosome paint. Y chromosome–
positive FISH signals (absent in the female controls and pres-
ent in the male controls) were observed in lung sections from
all the transplanted groups (Figure 3B). In sections of transplanted
lungs, these signals were localized mainly in areas of fibrosis.
BLM administration to rats results in an increase in collagen
deposition in the lung. Therefore, the amount of hydroxypro-
line, a modified amino acid specifically found in collagen (20),
was assessed to determine how alveolar type II transplantation
could alter the clinical course of BLM-induced lung injury.
BLM nontransplanted lungs showed a significant increase in the
amount of lung hydroxyproline when compared with saline
control rats (Figure 4A). In contrast, levels of hydroxyproline
were significantly reduced in all the BLM transplanted groups.
In the groups transplanted on Days 7 and 15 after BLM in-
stillation, we observed a greater reduction in hydroxyproline
levels, which did not significantly differ from levels observed in
the saline control groups. These results confirm that transplan-
tation of alveolar type II cells induces a reduction in collagen
deposition and, consequently, in the fibrotic response.
To further examine the effect of alveolar type II cell trans-
plantation in BLM-induced pulmonary fibrosis, serial lung sec-
tions were stained with hematoxylin–eosin or Masson’s trichrome
and examined by light microscopy. Lung tissue sections from
control rats showed no evidence of inflammation or epithelial
damage. As expected, lung tissue sections from rats with BLM-
induced fibrosis (nontransplanted) showed marked peribron-
chiolar and interstitial infiltration with inflammatory cells,
extensive cellular thickening of interalveolar septa, interstitial
edema, increased interstitial cells with a fibroblastic appearance,
excessive collagen deposition, and focal cuboidal metaplasia of
alveolar lining cells (Figure 4B, row a). The pattern of lesions
was multifocal (i.e., patchy areas of pulmonary fibrosis) and in
most cases involved the pleura. Although multifocal parenchy-
mal lesions were still present in lungs transplanted with alveolar
type II cells, the organized fibroblast foci were smaller and
considerably less frequent than were observed in nontrans-
planted animals. The reduction in parenchymal lesions was
evidenced by large areas of undamaged tissue with normal al-
veolar architecture (Figure 4B, row b). Compared with the
BLM nontransplanted group, BLM transplanted animals showed
less edema, less collagen deposition, less septal widening, and
fewer clusters of inflammatory cells.
Specificity of the alveolar type II cells to revert the fibrotic
process was verified in a group of animals transplanted with
macrophages (Figure 5). When macrophages were used for cell
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transplantation instead of alveolar type II cells, no beneficial
effects were observed. Body weight (Figure 5B), lung weight
(Figure 5C), and survival rate showed no significant differences
from the BLM nontransplanted group. In addition, hydroxypro-
line levels remained unmodified (Figure 5D) and the fibrotic
areas evaluated by light microscopy after hematoxylin–eosin
and Masson’s trichrome staining revealed a similar degree of
fibrosis compared with that observed in BLM nontransplanted
animals.
DISCUSSION
In this study, we demonstrate for the first time that intratracheal
transplantation of alveolar type II cells can halt and reverse
lung fibrosis. Alveolar epithelial damage is an important initial
event in pulmonary fibrosis. Epithelial cell damage and cell
death induce the formation of gaps in the epithelial basement
membranes. Migration of fibroblasts through these gaps into the
alveolar space leads to intraalveolar fibrosis. Normal repair of
the epithelial layer occurs through the proliferation of alveolar
type II cells and their subsequent differentiation to alveolar
type I cells necessary for proper lung function. In lung fibrosis,
however, the regenerative process is altered, with the number of
alveolar type II cells decreasing markedly in areas of severe
inflammation. Extensive injury and cell death follow (21, 22). In
areas of severe damage, alveolar type I and type II cells die
and are replaced by a large number of fibroblasts and smooth
muscle cells. The injury, together with the inadequate repair of
Figure 2. (A) Change in animal body weight over time. On Day 0, the animals received bleomycin (BLM). Arrowheads show the days of alveolar
type II cell transplantation (Trp) (Days 3, 7, and 15). (B) Representative photographs of whole lungs from all the experimental groups after 21 days of
BLM-induced lung fibrosis. Arrows show the scars in the BLM nontransplanted lung. BLM transplanted lungs showed an improved aspect compared
with BLM nontransplanted lungs. (C) Representative photographs of lung sections from all the experimental groups. Multifocal parenchymal lesions
were smaller in BLM transplanted lungs compared with BLM nontransplanted lungs. Scale bars: 1 mm. (D) Lung weight after 21 days of BLM-
induced lung fibrosis in experimental groups. Alveolar type II cells transplanted 7 or 15 days after BLM instillation reduced lung weight. Data
represent means 6 SEM of eight animals per group (*P , 0.05 vs. control groups, #P , 0.05 vs. BLM).
Figure 1. (A) Cytospin prepa-
ration showing alkaline phos-
phatase–positive cells. Original
magnification,3200. (B) Trans-
mission electron micrographs
of alveolar type II cells show-
ing lamellar bodies. Bar52 mm.
(C) Detail of the lamellar bod-
ies. Bar 51 mm.
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epithelial cells, disturbs normal epithelial–fibroblast interactions
and leads to pulmonary fibrosis.
Histologic and biochemical results show that transplantation
of alveolar type II cells in rats with BLM-induced lung fibrosis
can reverse the fibrogenic response. However, more studies are
needed to ascertain the mechanism whereby alveolar type II
cells induce recovery in the lung, as several causes could explain
this effect. First, the alveolar type II cells could limit the
deleterious effects of BLM by replacing already damaged alve-
olar epithelial type II cells, which are known to be targets of
apoptotic signals induced by BLM (22). Alveolar type II cells
are known to be the alveolar progenitor cells, which give rise to
alveolar type I cells in response to injury (23). Thus, trans-
plantation of alveolar type II cells may restore this pool, leading
to an increased number of alveolar cells for the resolution of
disrupted alveolar surfaces. In turn, this could promote the
repair process. Second, alveolar type II cells have a number of
physiological functions, including synthesis, secretion, and
turnover of pulmonary surfactant (23). Surfactant maintains
low surface tension at the air–liquid interface of the alveoli,
which is necessary for proper respiratory function. Transplan-
tation of alveolar type II cells could thus improve the mainte-
nance of normal lung function, promoting normal epithelial
repair. Third, alveolar type II cells could protect against BLM-
induced fibrosis by altering the lung microenvironment at sites
of engraftment, producing a number of cytokine antagonists
that disrupt signal pathways leading to fibrosis (23–26).Alveolar
type II cells are a rich source of chemokines, including inhibition
factors for fibroblast proliferation and secretion of collagen (27).
Therefore, secretion of these products from alveolar type II cells
could induce degradation of the new collagen deposition, halting
the development of lung fibrosis.
Figure 3. (A) Quantification of alveolar type II cell
engraftment in rat lung by real-time polymerase chain
reaction (PCR). Histogram of the data obtained in the
real-time PCR shows the percentage of male genomic
DNA within lung tissue from transplanted rats 21 days
after exposure to bleomycin (BLM). Data represent
means 6 SEM of eight animals per group (*P , 0.05
and 1P, 0.001 vs. control groups, #P, 0.05 and $P,
0.001 vs. BLM). (B) Detection of donor-derived alveo-
lar type II cells by fluorescence in situ hybridization
(FISH) of the Y chromosome. Shown are sections of
lung tissue hybridized with fluorescein isothiocyanate–
conjugated Y chromosome probe (green dots). Nuclei
are counterstained with propidium iodide (red). Arrows
indicate representative nuclei that contain the Y chro-
mosome in the transplanted groups.
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Figure 4. (A) Lung hydroxyproline levels after 21 days of bleomycin (BLM)-induced lung fibrosis. Alveolar type II cell transplantation reduced the
lung content of hydroxyproline at all times tested. Data represent means 6 SEM of eight animals per group (*P , 0.05 and 1P , 0.001 vs. control
groups, #P , 0.05 and $P , 0.001 vs. BLM). (B) Representative photomicrographs of lung histopathology in all the experimental groups after 21
days of BLM-induced lung fibrosis. Row a: Lung sections were stained with hematoxylin–eosin. Alveolar type II cell transplantation ameliorated the
inflammatory and pulmonary lesions. Original magnification, 3100. Row b: Masson’s trichrome of all the experimental groups. The presence of
interstitial collagen (blue staining) was diminished by alveolar type II cells in all the transplantation groups. Original magnification, 3100.
Figure 5. (A) Cytospin preparation showing alveolar macrophages. Original magnification, 3200. (B) Change in animal body weight over time. On
Day 0 the animals received BLM. Arrowheads show the day of macrophage transplantation (Day 15). (C) Lung weight after 21 days of BLM-induced
lung fibrosis in the experimental groups. (D) Lung hydroxyproline levels after 21 days of BLM-induced lung fibrosis. Macrophage transplantation did
not reduce the lung content of hydroxyproline. Data represent means 6 SEM of eight animals per group (1P , 0.001 vs. control groups). (E)
Representative photomicrographs of lung histopathology in all the macrophage experimental groups after 21 days of BLM-induced lung fibrosis.
Row a: Lung sections were stained with hematoxylin and eosin. Macrophage transplantation did not reduce inflammatory and pulmonary lesions.
Original magnification, 3100. Row b: Masson’s trichrome staining does not show a decrease in the presence of interstitial collagen (blue staining) in
the macrophage-transplanted group. Original magnification, 3100.
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The success of the method reported here could be due to the
fact that we used adult progenitor cells and the intratracheal
route for transplantation. This stands in contrast to earlier
reports, in which stem cells derived from adult tissues, such as
bone marrow–derived cells and mesenchymal stem cells, were
transplanted by the intravenous route (2–6). Previous studies
showed that bone marrow–derived cells transplanted intrave-
nously engrafted in different nonhematopoietic tissues and
acquired epithelial phenotypes, which suggested a new para-
digm for epithelial tissue repair (2). Nevertheless, the initial
enthusiasm vanished when subsequent studies either failed to
reproduce these initial results (28) or concluded that engraft-
ment events were due to transplanted cells fusing with endog-
enous somatic cells (28–32). One important caveat relates to the
intrinsic structure of the lung, in which each alveolus comprises
septae containing capillaries filled with circulating blood cells,
which could have been misinterpreted as bone marrow–derived
cells engrafted in the lung (33). In this regard, our method using
the intratracheal transoral route directly provides the necessary
cells for repairing the damaged lung. Because the origin of
fibroblasts in pulmonary fibrosis is assumed to be intrapulmo-
nary, the potential extrapulmonary origin of lung fibroblasts in
pulmonary fibrosis merits further investigation. Evidence sug-
gests that bone marrow–derived cells migrate to wound-healing
sites and serve as sources of fibroblasts and myofibroblasts,
which participate in the fibrotic process in response to the
signals released during lung injury and fibrosis (1, 2, 8, 33–35).
Therefore, it seems reasonable that the increase in these signals
could lead to migratory recruitment of transplanted bone
marrow–derived cells into the lung and could contribute to
the pathogenesis of lung fibrosis. By contrast, administration of
alveolar type II cells would provide the necessary cells for the
repair process. This notion has been confirmed by transplanta-
tion of macrophages, which did not improve the course of lung
fibrosis.
One important aspect of this study is the assignment of times
for alveolar type II cell transplantation. Transplantation was
performed at three different times after BLM-induced lung
injury: in the inflammatory phase (3 d after BLM instillation); in
the profibrotic phase (7 d after BLM instillation); and in the
fibrotic phase (15 d after BLM instillation), when the disease
was fully developed. This allowed us to determine the phase in
which transplantation could restore the damaged lung. Surpris-
ingly, our data indicate that alveolar type II cell transplantation
can halt the fibrogenic process at any of these times. It is im-
portant to take into account that at 3 and 7 days after BLM
instillation the fibroblasts are not growing yet, and therefore the
administration of alveolar type II cells could in this case be
preventing the fibrotic process.
For this reason, the most noteworthy result is the significant
reduction of fibrosis 15 days after BLM administration, when
the lungs are already fibrotic (21). Therefore, our data demon-
strate that the transplantation of alveolar type II cells is able to
reverse the fibrogenic process. In our opinion, this is a crucial
finding given the absence of a useful treatment for this lung
disease.
There are multiple therapeutic applications of this work.
Because the alveolar type II cells can be obtained by in vitro
differentiation of adult stem cells (36) and also by isolation from
lung biopsies, it would be possible to perform transplantation in
humans. Thus, adult stem cells could constitute an effective and
reproducible source of alveolar type II cells, which would allow
long-term treatment of lung fibrosis. Moreover, given the pro-
pensity of alveolar type II cells to engraft in damaged lung
tissue and their ability to restore epithelial damage, these cells
could also be an ideal target for gene therapy. Furthermore,
because the intratracheal route of administration is commonly
employed, this technique would be applicable to clinical practice.
In conclusion, these results show that intratracheal trans-
plantation of alveolar type II cells could become a promising
therapy for the future treatment of fibrotic lung diseases.
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